From the Research
Hyperbaric oxygen therapy (HBOT) may be considered as a complementary treatment for certain cases of Inflammatory Bowel Disease (IBD), particularly for hospitalized ulcerative colitis flares and Crohn's disease-related fistulae, as suggested by the most recent and highest quality study 1.
Key Points to Consider
- The evidence for HBOT in IBD is growing, with several studies suggesting its potential benefits in reducing inflammation and promoting tissue healing 2, 1, 3.
- However, the quality of the evidence is generally low, and more high-quality trials are needed to confirm the efficacy of HBOT in IBD 2, 1.
- HBOT is not currently recommended as a standard treatment for IBD, and conventional treatments, including anti-inflammatory medications, immunomodulators, biologics, and surgical intervention, remain the primary approach to managing the disease.
- The use of HBOT as a complementary therapy should be considered on a case-by-case basis, under the guidance of a gastroenterologist and a specialist in hyperbaric medicine.
Potential Benefits and Risks
- The potential benefits of HBOT in IBD include reduced inflammation, promoted tissue healing, and improved symptoms 2, 1, 3.
- However, HBOT is expensive, not widely available, and requires multiple sessions over weeks or months, which may be a significant burden for patients.
- The risk of adverse events associated with HBOT is generally low, with most studies reporting minor adverse events 2, 1, 3.
Conclusion Not Applicable - Direct Answer Only
In summary, while the evidence for HBOT in IBD is promising, it is essential to approach its use with caution and consider it as a complementary therapy only in specific cases, under the guidance of a specialist 1.